

An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression

Daryl DeKarske^{a,*}, Gustavo Alva^b, Jason L. Aldred^c, Bruce Coate^a, Marc Cantillon^d, Lori Jacobi^a, Rene Nunez^a, James C. Norton^{a,1} and Victor Ablor^a

^aACADIA Pharmaceuticals Inc., San Diego, CA, USA

^bDepartment of Neuroscience, University of California, Riverside, Riverside, CA, USA

^cSelkirk Neurology, PLLC, Spokane, WA, USA

^dDepartment of Neurology and Psychiatry, Robert Wood Johnson Medical School, New Brunswick, NJ, USA

Accepted 17 July 2020

Abstract.

Background: Many patients with Parkinson's disease (PD) experience depression.

Objective: Evaluate pimavanserin treatment for depression in patients with PD.

Methods: Pimavanserin was administered as monotherapy or adjunctive therapy to a selective serotonin reuptake inhibitor or serotonin/noradrenaline reuptake inhibitor in this 8-week, single-arm, open-label phase 2 study (NCT03482882). The primary endpoint was change from baseline to week 8 in Hamilton Depression Scale–17-item version (HAMD-17) score. Safety, including collection of adverse events and the Mini-Mental State Examination (MMSE) and Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) scores, was assessed in patients who received ≥ 1 pimavanserin dose.

Results: Efficacy was evaluated in 45 patients (21 monotherapy, 24 adjunctive therapy). Mean (SE) baseline HAMD-17 was 19.2 (3.1). Change from baseline to week 8 (least squares [LS] mean [SE]) in the HAMD-17 was -10.8 (0.63) (95% CI, -12.0 to -9.5 ; $p < 0.0001$) with significant improvement seen at week 2 ($p < 0.0001$) and for both monotherapy (week 8, -11.2 [0.99]) and adjunctive therapy (week 8, -10.2 [0.78]). Most patients (60.0%) had $\geq 50\%$ improvement at week 8, and 44.4% of patients reached remission (HAMD-17 score ≤ 7). Twenty-one of 47 patients experienced 42 treatment-emergent adverse events; the most common by system organ class were gastrointestinal ($n = 7$; 14.9%) and psychiatric ($n = 7$; 14.9%). No negative effects were observed on MMSE or MDS-UPDRS Part III.

Conclusion: In this 8-week, single-arm, open-label study, pimavanserin as monotherapy or adjunctive therapy was well tolerated and associated with early and sustained improvement of depressive symptoms in patients with PD.

Keywords: Parkinson's disease, depression, dementia, pimavanserin, adjunctive therapy, monotherapy

¹Current affiliation is Arena Pharmaceuticals, San Diego, CA, USA

*Correspondence to: Daryl DeKarske, MPH, ACADIA Pharmaceuticals Inc., 3611 Valley Centre Drive, Ste 300, San

Diego, CA 92130-3331, USA. Tel.: +1 858 320 8683; E-mail: ddekarske@acadia-pharm.com.

INTRODUCTION

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized primarily by motor deficits; however, behavioral symptoms associated with the disease are frequent, severe, and disabling [1]. Mood disorders, including depression, occur in 30% to 50% of patients [1, 2]. Depression can emerge at any phase of the disease [1] and is associated with faster progression of physical symptoms, disability, and diminished quality of life [3]. Conversely, improvement of depression in patients with PD correlates with reduced physical disability and improved quality of life [3].

Despite the significant need for treatment, no medications are currently approved by the United States Food and Drug Administration (US FDA) for depression in patients with PD. A paucity of studies have examined currently approved antidepressants for treating depression in patients with PD [4–7] and suggest either no benefit or only marginal effects.

Widespread neurodegeneration and monoaminergic dysregulation, particularly in the mesolimbic system, can contribute to depression [8, 9]. While the exact pathophysiology is unknown, key features of depression, including depressed mood, apathy, and anhedonia, are known to be related to serotonergic transmission that is dysregulated in PD [9–11]. Compounds with potent antagonist/inverse agonist activity at 5-hydroxytryptamine 2A (5-HT_{2A}) receptors, and to varying degrees at 5-hydroxytryptamine 2C (5-HT_{2C}) receptors, but with lower affinity for monoamine transporters, have shown antidepressant effects in major depressive disorder patient populations [12, 13].

Pimavanserin is a selective 5-HT_{2A} receptor antagonist/inverse agonist with limited affinity for 5-HT_{2C}

receptors [14]. Based on its mechanism of action, pimavanserin may have antidepressant activity. In a phase 2 randomized, controlled trial, adjunctive pimavanserin treatment improved symptoms of major depressive disorder (MDD) in patients with an inadequate response to selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI) treatment [15]. The current study was intended to preliminarily assess the efficacy and safety of pimavanserin being investigated for the treatment of depression in patients with PD.

METHODS

Study design

This was an 8-week, open-label, single-arm phase 2 study to evaluate the efficacy and safety of pimavanserin for treatment of depression in patients with PD. During the study, patients were given pimavanserin 34 mg (two 17 mg tablets) with instructions to take the medication orally at approximately the same time daily. Assessments were conducted every 2 weeks, and patients received a safety follow-up call 2 weeks after the last dose of the pimavanserin (Fig. 1).

The study was conducted between March 9, 2018, and July 24, 2019 (ClinicalTrials.gov identifier: NCT03482882). All procedures were conducted in accordance with the Declaration of Helsinki and applicable International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice guidelines. The protocol was approved by each site's ethics committee or institutional review board and all participants provided informed consent.




Fig. 1. Study design. PD, Parkinson's disease; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

99 *Patient eligibility*

100 Patients in the United States aged ≥ 50 years with
 101 PD and depression [16] were recruited. Patients were
 102 required to have a clinical diagnosis of PD for ≥ 1
 103 year with ≥ 3 symptoms of PD (rest tremor, rigidity,
 104 bradykinesia or akinesia, or postural/gait abnormal-
 105 ities), be on anti-PD medication for ≥ 1 year, and
 106 exhibit a Mini-Mental State Examination (MMSE
 107 [17]) score of ≥ 21 .

108 PD patients with depressive symptoms (score
 109 of ≥ 15 on the Hamilton Depression Scale–17-
 110 item version (HAMD-17 [18]) and who met the
 111 National Institute of Neurological Disorders and
 112 Stroke–National Institute of Mental Health criteria for
 113 depression in patients with PD [16]) were eligible to
 114 enroll. Those taking a single SSRI or SNRI within the
 115 US FDA approved labeling for the treatment of major
 116 depressive disorder were eligible if their current treat-
 117 ment was inadequate. If patients were taking more
 118 than one antidepressant, they were eligible to enroll
 119 if they were being discontinued from one agent before
 120 the baseline visit in a clinically appropriate manner.

121 Patients were excluded if they were taking or had
 122 taken an antipsychotic medication (within 3 weeks
 123 or 5 half-lives of the baseline visit [whichever is
 124 longer]); had a history of PD psychosis, schizophre-
 125 nia, bipolar I or II disorder, another psychotic
 126 disorder, or substance use disorder (within the last
 127 6 months); or were actively suicidal. Individuals
 128 with a history of stroke, a family history of a long
 129 QT syndrome, or a myocardial infarction were also
 130 excluded. Full inclusion/exclusion criteria are listed
 131 in Supplementary Table 1. Adjunctive medications
 132 for Parkinson's disease or depression were kept stable
 133 for the duration of the study if possible.

134 *Outcomes and assessments*

135 The primary objective of the study was to assess
 136 the efficacy of pimavanserin treatment, as monother-
 137 apy or adjunctive therapy, in improving depression
 138 symptoms in adults with PD. The primary endpoint
 139 was assessed based on the change from baseline
 140 to week 8 in depression symptoms as measured
 141 by the HAMD-17 [18]. The proportion of patients
 142 showing $\geq 50\%$ improvement in the HAMD-17 score
 143 was evaluated as a secondary endpoint. A *post hoc*
 144 analysis examined the proportion of patients who
 145 reached remission, defined as a HAMD-17 score
 146 of ≤ 7 [19]. The HAMD-17 was administered at
 147 screening, baseline, and weeks 2, 4, 6, and 8.

Table 1
 Baseline demographics and disease characteristics

Characteristic	N = 45
Age, y	
Mean (SD)	69.3 (8.3)
Range	51–89
Age category, n (%)	
<70	20 (44.4)
≥ 70	25 (55.6)
Male, n (%)	23 (51.1)
Female, n (%)	22 (48.9)
Race, n (%)	
White	41 (91.1)
Black or African American	2 (4.4)
Asian	1 (2.2)
Other	1 (2.2)
Age at PD onset, mean (SD), y	61.5 (9.9)
Duration of PD, mean (SD), y	7.8 (5.5)
Age at onset of depression with PD (SD), y	63.9 (10.9)
Duration of depression with PD (SD), y	5.4 (6.8)
MMSE score, mean (SD)	27.6 (2.5)
MDS-UPDRS Part III score, mean (SD)	30.5 (17.3)
Assessment score, mean (SD)	
HAMD-17	19.2 (3.1)
CGI-S	4.1 (0.5)
SCOPA-NS	6.1 (3.4)
SCOPA-DS	5.2 (3.7)
SCOPA-GS	3.9 (1.5)
EQ-5D-5L-VAS	63.9 (16.3)

CGI-S, Clinical Global Impression–Severity; HAMD-17, Hamil-
 ton Depression Scale–17-item version; MDS-UPDRS, Movement
 Disorder Society–sponsored revision of the Unified Parkinson's
 Disease Rating Scale; MMSE, Mini-Mental State Examination;
 PD, Parkinson's disease; SCOPA-DS, Scale for Outcomes in
 Parkinson's Disease–daytime sleepiness; SCOPA-GS, Scale for
 Outcomes in Parkinson's Disease–global sleep; SCOPA-NS, Scale
 for Outcomes in Parkinson's Disease–nighttime sleep; EQ-5D-
 5L-VAS, EuroQol-5 Dimensions-5 Levels Proxy version 1 visual
 analog scale; SD, standard deviation.

148 Secondary endpoints evaluated the effect of pima-
 149 vanserin treatment on clinicians' global assessment
 150 of illness, sleep quality, and overall quality of life.
 151 Global impression of illness was assessed by the Clin-
 152 ical Global Impression–Improvement (CGI-I) score
 153 and change from baseline on the Clinical Global
 154 Impression–Severity (CGI-S) score [20]. Changes in
 155 sleep quality were evaluated as change from base-
 156 line in the Scale for Outcomes of PD–Sleep Scale
 157 (SCOPA) score, including global sleep (GS) quality,
 158 nighttime sleep (NS) quality, and daytime sleepiness
 159 (DS) [21]. Patients' quality of life was assessed by a
 160 caregiver as change from baseline in the EuroQol-5
 161 Dimensions-5 Levels Proxy version 1 visual analog
 162 scale (EQ-5D-5L-VAS) [22]. The CGI-S and CGI-I
 163 were assessed at baseline and weeks 2, 4, 6, and 8.
 164 SCOPA and EQ-5D-5L-VAS were assessed at base-
 165 line and at weeks 4 and 8.

Medical history and demographic information were collected during screening. The MMSE [17] and Columbia-Suicide Severity Rating Scale (C-SSRS) scores [23] were used to screen for cognitive impairment and suicidal ideation. Both measures were also collected as safety assessments. The MMSE was administered at screening, baseline, week 4, and week 8. The C-SSRS was administered at screening, baseline, and weeks 2, 4, 6, and 8. The Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH ATRQ) [24, 25] was used as a screening assessment. The MGH ATRQ assesses response to antidepressant treatment retrospectively using specific anchor points throughout treatment history to define the adequacy of the dose and duration of each antidepressant course. Patients exhibiting a maximum improvement of <75% with an existing antidepressant were included in the adjunctive therapy group.

Safety endpoints, including the MMSE, C-SSRS, physical examinations, vital signs, clinical laboratory tests, electrocardiograms, and incidence of adverse events (AEs) were monitored throughout the study. A treatment-emergent AE (TEAE) was defined as an AE with onset date during treatment or within 30 days of the last study drug dose date. The relationship to treatment was reported by the investigator. A serious AE was defined as an AE that was fatal, was immediately life-threatening, resulted in disability or permanent damage, required hospitalization, was a congenital anomaly or birth defect in an offspring, or was medically significant.

The Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (MDS-UPDRS III) [26], a comprehensive measure of motor indices, was also included to assess any decline in motor function. This assessment was completed in the "on" state and was conducted at baseline, week 4, and week 8; change from baseline was analyzed.

Statistical analysis

Patients who received ≥ 1 dose of pimavanserin and completed a baseline and ≥ 1 postbaseline HAMD-17 assessment were included in the efficacy analysis. The mixed model repeated measures (MMRM) method was used to analyze primary and secondary endpoints. The total score of each measure was analyzed, with change from baseline as the dependent variable and baseline total score (of the dependent variable), visit (weeks 2, 4, 6, and 8), and base-

line total score-by-visit interaction as independent variables. Treatment effects were reported as the least squares (LS) mean (standard error [SE]) change from baseline to week 8. The CGI-I was analyzed using the MMRM with CGI-I score as the dependent variable, and with independent variables of baseline CGI-S score, visit, and baseline CGI-S score-by-visit interaction. Significance level was set to 0.05 and p values reported for pre-planned secondary outcomes were unadjusted for multiple comparisons.

The proportion of patients showing a response to treatment was reported by visit. Responders were defined as patients who exhibited $\geq 50\%$ reduction from baseline score in the HAMD-17. Observed cases (patients with missing values at a given visit were excluded) and missing values imputed as nonresponders were included.

In a *post hoc* analysis, the proportion of patients reaching remission, defined as a HAMD-17 score ≤ 7 , was reported by visit. Missing values were imputed as nonremitters. Improvement on individual items of the HAMD-17 was also analyzed *post hoc* using an MMRM similar to the primary endpoint.

Patients who received ≥ 1 dose of pimavanserin were included in the safety analysis. Safety endpoints were summarized using descriptive statistics. The MMSE and MDS-UPDRS Part III were analyzed using an MMRM similar to the primary endpoint.

RESULTS

Patients

Forty-seven patients were enrolled in the study from 14 sites in the United States. Forty-five patients were included in the efficacy analyses. Patients had a mean (standard deviation [SD]) age at baseline of 69.3 (8.3) years and a mean (SD) MMSE score of 27.6 (2.5). The mean (SD) time since PD diagnosis and duration of depression with PD diagnoses was 7.8 (5.5) years and 5.4 (6.8) years, respectively (Table 1). At baseline, patients were "Moderately Depressed" on average, with a mean (SD) HAMD-17 score of 19.2 (3.1), and a range of 15 ("Mild Depression") to 27 ("Severe Depression") [19]. The mean (SD) time since the first use of an antidepressant was 5.4 (5.9) years. Forty patients completed the study and 7 (14.9%) discontinued. Reasons for discontinuation were adverse event ($n = 3$, 6.4%), protocol violation ($n = 2$, 4.3%), loss to follow up ($n = 1$, 2.1%), or other event (medical monitor decision, $n = 1$, 2.1%).

Table 2
Change in CGI-S and CGI-I scores over 8 weeks of treatment with pimavanserin as monotherapy vs adjunctive therapy

		Monotherapy		Adjunctive Therapy	
CGI-S	n	Change from baseline LS mean (SE)	n	Change from baseline LS mean (SE)	
Week 2	20	-1.1 (0.18)	23	-0.9 (0.23)	
Week 4	20	-1.5 (0.19)	19	-1.5 (0.21)	
Week 6	18	-1.7 (0.20)	21	-1.5 (0.18)	
Week 8	19	-1.9 (0.21)	20	-1.6 (0.22)	
CGI-I	n	Change from baseline LS mean (SE)	n	Change from baseline LS mean (SE)	
Week 2	19	2.4 (0.21)	23	2.6 (0.26)	
Week 4	20	2.1 (0.20)	19	2.3 (0.23)	
Week 6	18	1.9 (0.19)	21	2.2 (0.22)	
Week 8	19	1.8 (0.20)	20	2.2 (0.25)	

Clinicians rated the severity of the patient's depression and improvement of symptoms from baseline on a scale of 1–7, with lower scores indicating improvement. CGI-I, Clinical Global Impression–Improvement; CGI-S, Clinical Global Impression–Severity; LS, least squares; SE, standard error.

Twenty-six enrolled patients were administered pimavanserin as adjunctive therapy with one of the following: bupropion, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, or vortioxetine. Dosage and number of patients taking each are presented in Supplementary Table 2. Twenty-four patients (53.3%) taking pimavanserin as adjunctive therapy were included in the primary efficacy analysis. The MGH ATRQ revealed that 14 (58.3%) of 24 patients included in the adjunctive therapy group reported, a maximum improvement <50% with their existing antidepressant medication at screening and 10 (41.7%) of 24 patients reported a maximum improvement of 50% to <75%. Patients had been taking antidepressant medication for a minimum of 3 months, and the mean (SE) duration of antidepressant use was 49.0 (12.68) months. For those who discontinued a second antidepressant, the second antidepressant was discontinued within the 21-day screening period prior to the baseline visit. In patients in the adjunctive therapy group, the baseline mean (SD) HAMD-17 score was 19.2 (3.8), with a range of 15 to 27.

Twenty-one patients (46.7%) who received pimavanserin as monotherapy were included in the primary efficacy analysis. In these patients, baseline mean (SD) HAMD-17 score was 19.1 (2.1), with a range of 16 to 23.

Changes in depressive symptoms in PD

In the primary analysis, which included both monotherapy and adjunctive therapy, patients showed a significant improvement in depression symptoms, as indicated by a significant reduction in the HAMD-17 score at week 8 (LS mean [SE] change, -10.8

[0.63]; 95% CI, -12.0 to -9.5; $p < 0.0001$), with significant improvement seen as early as week 2 (-7.3 [0.85]; 95% CI, -9.0 to -5.6; $p < 0.0001$) (Fig. 2A). Patients showed significant improvement on all 17 individual items of the HAMD-17 in the *post hoc* analysis (Fig. 2B).

Patients receiving pimavanserin as monotherapy showed significant improvement in depression symptoms, as indicated by a reduction at week 8 in the HAMD-17 (LS mean [SE] change, -11.2 [0.99]; 95% CI, -13.3 to -9.1; $p < 0.0001$). Again, significant improvements were seen starting at week 2 (Fig. 3A). Patients receiving pimavanserin as adjunctive therapy also exhibited a significant reduction in HAMD-17 score at week 8 (LS mean [SE] change, -10.2 [0.78]; 95% CI, -11.8 to -8.6; $p < 0.0001$), with significant improvement starting at week 2 (Fig. 3B).

By week 2, 16, of 45 patients (35.6%; 95% CI, 23.2 to 50.2) showed a response to treatment (HAMD-17 improvement $\geq 50\%$ from baseline). This level of improvement was observed in 22 patients (48.9%; 95% CI, 35.0 to 63.0) at week 4, 25 patients (55.6%; 95% CI, 41.2 to 69.1) at week 6, and 27 patients (60.0%; 95% CI, 45.5 to 73.0) at week 8. Remission (HAMD-17 score ≤ 7) was achieved by 10 of 45 patients (22.2%; 95% CI, 12.5 to 36.3) at week 2, 14 patients (31.1%; 95% CI, 19.5 to 45.7) at week 4, and 20 patients (44.4%; 95% CI, 30.9 to 58.8) at weeks 6 and 8. Two patients at week 2 and 6 patients at weeks 4 and 6 were imputed as nonresponders/nonremitters, respectively.

Changes in secondary clinical outcomes

In the overall study population, symptom severity was decreased, as indicated by a LS mean [SE]




Fig. 2. Change from baseline in HAMD-17 (A) total score over 8 weeks and (B) individual item scores at week 8 in all patients included in efficacy analyses. BL, baseline; HAMD-17, Hamilton Depression Scale-17-item version; LS, least squares; SE, standard error.




Fig. 3. Change in HAMD-17 from baseline by treatment with pimavanserin as (A) monotherapy and (B) adjunctive therapy. BL, baseline; HAMD-17, Hamilton Depression Scale-17-item version; LS, least squares; SE, standard error.

333 change from baseline at week 8 in the CGI-S of -1.7
 334 $[0.16]$ (95% CI, -2.1 to -1.4 ; $p < 0.0001$) (Fig. 4A),
 335 though the significance level for all secondary out-
 336 comes was not adjusted for pre-planned multiple
 337 comparisons. Consistent with this, the CGI-I score
 338 also indicated improvement following 8 weeks of
 339 pimavanserin treatment (LS mean [SE], 2.0 $[0.16]$;

95% CI, 1.7 to 2.3) (Fig. 4B). Reductions were
 also observed for both monotherapy and adjunctive
 therapy (Table 2).

Patients also reported an improvement in sleep
 quality. LS mean [SE] change from baseline in GS
 quality (SCOPA-GS) at week 8 was -1.0 $[0.23]$
 (95% CI, -1.5 to -0.6 ; $p < 0.0001$) (Fig. 5A). Both

340
 341
 342
 343
 344
 345
 346




Fig. 4. Impact on (A) CGI-S and (B) CGI-I scores over 8 weeks in all patients included in efficacy analyses. BL, baseline; CGI-I, Clinical Global Impression–Improvement; CGI-S, Clinical Global Impression–Severity; LS, least squares; SE, standard error.




Fig. 5. Change from baseline to week 8 in (A) SCOPA-GS, (B) SCOPA-NS, and (C) SCOPA-DS in all patients included in efficacy analyses. BL, baseline; LS, least squares; SCOPA-DS, Scale for Outcomes in Parkinson's Disease–daytime sleepiness; SCOPA-GS, Scale for Outcomes in Parkinson's Disease–global sleep; SCOPA-NS, Scale for Outcomes in Parkinson's Disease–nighttime sleep; SE, standard error.

347 NS (SCOPA-NS; LS mean [SE], -2.1 [0.48], 95%
 348 CI, -3.1 to -1.1; $p < 0.0001$) (Fig. 5B) and DS
 349 (SCOPA-DS; LS mean [SE], -2.2 [0.33], 95%
 350 CI, -2.8 to -1.5; $p < 0.0001$) (Fig. 5C) were also
 351 improved at week 8. Similarly, pimavanserin treat-
 352 ment improved caregivers' perception of patients'
 353 quality of life, as indicated by an increase from base-
 354 line in EQ-5D-5L-VAS score at week 8 (LS mean
 355 [SE], 7.0 [2.46]; 95% CI, 2.1 to 12.0; $p = 0.0068$)
 (Fig. 6).

Safety

356
 357 The safety analyses included 47 patients. Twenty-
 358 one patients experienced 42 TEAEs, with most in
 359 the system organ classes (SOC) of gastrointestinal
 360 ($n = 7$, 14.9%) and psychiatric ($n = 7$, 14.9%). The
 361 most common events by preferred term, across all
 362 SOC, were fall ($n = 4$, 8.5%), nausea ($n = 3$, 6.4%),
 363 diarrhea ($n = 2$, 4.3%), edema ($n = 2$, 4.3%), skin abra-
 364 sion ($n = 2$, 4.3%), and urinary tract infection ($n = 2$,




Fig. 6. Change from baseline to week 8 in EQ-5D-5L-VAS in all patients included in efficacy analyses. BL, baseline; EQ-5D-5L-VAS, EuroQol-5 Dimensions-5 Levels version 1 visual analog scale; LS, least squares; SE, standard error.

4.3%) (Table 3). Twelve events in 8 patients were considered to be related to treatment. One serious TEAE of colitis was reported and was not considered to be related to treatment. No deaths were reported.

No change from baseline was observed in cognitive function, as measured by the MMSE, at either week 4 (LS mean [SE], 0.3 [0.26]; $p=0.2078$) or week 8 (LS mean [SE], 0.4 [0.25]; $p=0.1266$). Furthermore, no clinically significant changes induced by pimavanserin regarding cardiovascular safety were reported. No patients exhibited a QTcF of >500 ms or a change from baseline of >60 ms at any point during the study. At baseline, the mean (SE) QTcF interval was 411.0 (3.01) ms. After 8 weeks of pimavanserin treatment, the mean (SE) QTcF interval was 416.8 (3.33) ms, with a mean change from baseline of 8.4 (2.26) ms (range, -18 to 39).

In the safety analysis, no negative effect of pimavanserin on motor function was observed. In contrast, we observed a statistically significant improvement in motor function, as measured by the MDS-UPDRS III, at both week 4 ($p=0.0023$) and week 8 ($p=0.0007$) (Fig. 7).

Table 3

Summary of treatment-emergent adverse events

Patients with Treatment-Emergent Adverse Events (TEAEs), n (%)	Safety Population (N = 47)
Any TEAE	21 (44.7)
Any serious TEAE	1 (2.1)
TEAEs by MedDRA preferred term	
Fall	4 (8.5)
Nausea	3 (6.4)
Diarrhea	2 (4.3)
Edema	2 (4.3)
Skin abrasion	2 (4.3)
Urinary tract infection	2 (4.3)
Abdominal pain	1 (2.1)
Abnormal dreams	1 (2.1)
Blood glucose increased	1 (2.1)
Blood pressure increased	1 (2.1)
Colitis	1 (2.1)
Constipation	1 (2.1)
Contusion	1 (2.1)
Dizziness	1 (2.1)
Gastritis	1 (2.1)
Gout	1 (2.1)
Hallucination, auditory	1 (2.1)
Hallucination, visual	1 (2.1)
Hypertonia	1 (2.1)
Hypothyroidism	1 (2.1)
Illusion	1 (2.1)
Insomnia	1 (2.1)
Laceration	1 (2.1)
Mental impairment	1 (2.1)
Muscle strain	1 (2.1)
Non-cardiac chest pain	1 (2.1)
Palpitations	1 (2.1)
Peripheral swelling	1 (2.1)
Presyncope	1 (2.1)
Rapid eye movement sleep behaviour disorder	1 (2.1)
Suicidal ideation	1 (2.1)
Supraventricular extrasystoles	1 (2.1)
Vomiting	1 (2.1)

MedDRA, Medical Dictionary for Regulatory Activities. Version 20.0.

DISCUSSION

These data from a single-arm, open-label 8-week study suggest that pimavanserin is associated with early and sustained improvement of depression symptoms in patients with PD. By week 8, 60.0% of patients showed $\geq 50\%$ improvement in symptoms on the HAMD-17, and 44.4% of patients reached remission (HAMD-17 score ≤ 7) at week 6, which was sustained through week 8. Further, similar improvements were seen in patients administered pimavanserin as monotherapy and patients administered pimavanserin as adjunctive therapy with an SSRI or SNRI. Treatment was associated




Fig. 7. Change from baseline to week 8 in MDS-UPDRS Part III in all patients included in safety analysis. BL, baseline; LS, least squares; MDS-UPDRS Part III, Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III; SE, standard error.

with improvements in global assessments of disease severity, quality of sleep, and overall quality of life.

Few studies evaluating currently approved antidepressants for treatment of PD patients with depression have been conducted, and these studies have shown no or marginal improvement of depressive symptoms [4, 7]. Importantly, antidepressant treatments may take several weeks to achieve efficacy for those who do experience some therapeutic benefits [27]. The latency period between the initiation treatment and the onset of the therapeutic benefit exacerbates the public health burden and increases risks for suicide or self-harm [27]. In this study, improvements in depressive symptoms emerged by the first study visit, 2 weeks after the start of treatment, with continued improvement throughout the 8-week study. These results suggest that pimavanserin has the potential for rapid antidepressant efficacy in patients with PD.

Management of depression in patients with PD is a critical component of treatment that influences quality of life [3]. Although the HAMD-17 was not developed primarily for use in PD patients and includes some questions about symptoms that may overlap with the symptoms of PD [18], it has good sensitivity in PD populations [28–30]. Patients in this study exhibited stable symptoms of PD but

strong improvements on the HAMD-17 following pimavanserin treatment. Consistent with this, patients also experienced improvements on both physician-reported and patient-reported outcomes, such as the CGI and the SCOPA.

Pimavanserin was well tolerated and safety outcomes were consistent with those from other studies of pimavanserin treatment in patients with PD [31, 32]. The most common TEAEs were fall, nausea, diarrhea, edema, skin abrasion, and urinary tract infection. Interestingly, an improvement in motor function was observed, as indicated by an LS mean reduction from baseline to week 8 of 5.1 on the MDS-UPDRS Part III.

Although the pimavanserin treatment results compared with baseline were robust and were consistent with improvements seen in the recent placebo-controlled trial showing efficacy for pimavanserin as an adjunctive treatment in MDD [15], this study was an open-label, single-arm design trial. Because eligible patients were required to have depressive symptoms based on HAMD-17 score, regression to the mean may have contributed to improvements observed on this measure, although the consistent improvement observed across measures supports the strength of the results. The small sample size and lack of a placebo comparator group in this study limit the generalizability of the results. Placebo-controlled studies will be needed to further determine the efficacy of pimavanserin in treating depression in patients with PD.

Patients with PD represent a clinical population with an unmet need for effective pharmacotherapies to improve depressive symptoms. Overall, these results suggest that pimavanserin treatment may be a potential therapeutic opportunity for further evaluation for improvement of depression in patients with PD.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the patients and clinicians who participated in this study. ACADIA Pharmaceuticals Inc. (San Diego, CA, USA) provided funding for medical writing and editorial support in the development of this manuscript. Meghan Jones, PhD (Ashfield Healthcare Communications, Middletown, CT) provided writing support based on input from authors, and Mary Kacillas and Dena McWain (Ashfield Healthcare Communications) copyedited and styled the manuscript per journal requirements.

Disclosures

DD, BC, LJ, RN, VA: are employees of and hold stock and/or stock options in ACADIA Pharmaceuticals Inc.

JCN: was an employee of ACADIA Pharmaceuticals Inc. at the time of this study.

GA: has received research support from Accera, Allergan, Axovant, Eisai, Genentech, Intra-Cellular, Janssen, Lundbeck, Neurim, Neurotrope, Novartis, Otsuka, Roche, Suven, and TransTech and has served on the speakers bureau or as a consultant for ACADIA, Alkermes, Allergan, Avanir, Janssen, Lundbeck, Merck, Nestlé, Otsuka, Sunovion, Takeda, and Vanda.

JLA: has received research support from Abbott, AbbVie, ACADIA, Biogen, Boston Scientific, Denali, Impax, NeuroDerm, Sunovion, and Theravance and has received honoraria from Abbott, AbbVie, Acorda, Adamas, Allergan, Boston Scientific, Medtronic, Teva, and US WorldMeds.

MC is a consultant to ACADIA, Kyowa Kirin, Sunovion, and Reviva.

Data sharing statement

Data available on request from authors: The data that support the findings of this study are available from the corresponding author upon reasonable request.

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: <https://dx.doi.org/10.3233/JPD-202058>.

REFERENCES

- [1] Marsh L (2013) Depression and Parkinson's disease: Current knowledge. *Curr Neurol Neurosci Rep* **13**, 409.
- [2] Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP (2001) Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. *J Neuropsychiatry Clin Neurosci* **13**, 187-196.
- [3] Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A (2009) The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. *Mov Disord* **24**, 1325-1332.
- [4] Liu J, Dong J, Wang L, Su Y, Yan P, Sun S (2013) Comparative efficacy and acceptability of antidepressants in Parkinson's disease: A network meta-analysis. *PLoS One* **8**, e76651.
- [5] Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa CJ (2013) Antidepressants for depression in Parkinson's disease: Systematic review and meta-analysis. **27**, 417-423.
- [6] Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S (2015) Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. *Parkinsonism Relat Disord* **21**, 833-842; discussion 833.
- [7] Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, Katz IR, Stern MB (2005) Antidepressant studies in Parkinson's disease: A review and meta-analysis. *Mov Disord* **20**, 1161-1169.
- [8] Prange S, Metereau E, Thobois S (2019) Structural imaging in Parkinson's disease: New developments. *Curr Neurol Neurosci Rep* **19**, 50.
- [9] Thobois S, Prange S, Sgambato-Faure V, Tremblay L, Broussolle E (2017) Imaging the etiology of apathy, anxiety, and depression in Parkinson's disease: Implication for treatment. *Curr Neurol Neurosci Rep* **17**, 76.
- [10] Takahashi M, Tabu H, Ozaki A, Hamano T, Takeshima T, group Rs (2019) Antidepressants for depression, apathy, and gait instability in Parkinson's disease: A multicenter randomized study. *Intern Med* **58**, 361-368.
- [11] Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF (2016) Major depressive disorder. *Nat Rev Dis Primers* **2**, 16065.
- [12] Celada P, Puig M, Amargós-Bosch M, Adell A, Artigas F (2004) The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression. *J Psychiatry Neurosci* **29**, 252-265.
- [13] Fornaro M, Fusco A, Anastasia A, Cattaneo CI, De Berardis D (2019) Brexpiprazole for treatment-resistant major depressive disorder. *Expert Opin Pharmacother* **16**, 1925-1933.
- [14] Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H (2014) On the discovery and development of pimavanserin: A novel drug candidate for Parkinson's psychosis. *Neurochem Res* **39**, 2008-2017.
- [15] Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S (2019) A Phase 2, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY). *J Clin Psychiatry* **80**, 19m12928.
- [16] Marsh L, McDonald WM, Cummings J, Ravina B, NINDS/NIMH Work Group on Depression and Parkinson's Disease (2006) Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. *Mov Disord* **21**, 148-158.
- [17] Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* **12**, 189-198.
- [18] Hamilton M (1960) A rating scale for depression. *J Neurol Neurosurg Psychiatry* **23**, 56-62.
- [19] Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K (2013) Severity classification on the Hamilton Depression Rating Scale. *J Affect Disord* **150**, 384-388.
- [20] Guy W (1976) Clinical Global Impressions. In: *ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW publication number ADM 76-338)*, 218-222.
- [21] Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM (2003) Assessment of sleep and sleepiness in Parkinson disease. *Sleep* **26**, 1049-1054.
- [22] Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* **20**, 1727-1736.

- 589 [23] Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, 616
590 Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen 617
591 S, Mann JJ (2011) The Columbia-Suicide Severity Rating 618
592 Scale: Initial validity and internal consistency findings from 619
593 three multisite studies with adolescents and adults. *Am J 620*
594 *Psychiatry* **168**, 1266-1277. 621
- 595 [24] Fava M (2003) Diagnosis and definition of treatment- 622
596 resistant depression. *Biol Psychiatry* **53**, 649-659. 623
- 597 [25] Fava M, Davidson KG (1996) Definition and epidemiology 624
598 of treatment-resistant depression. *Psychiatr Clin North Am 625*
599 **19**, 179-200. 626
- 600 [26] Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio 627
601 C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, 628
602 Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, 629
603 Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, 630
604 Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Move- 631
605 ment Disorder Society-sponsored revision of the Unified 632
606 Parkinson's Disease Rating Scale (MDS-UPDRS): Process, 633
607 format, and clinimetric testing plan. *Mov Disord* **22**, 41-47. 634
- 608 [27] Machado-Vieira R, Henter ID, Zarate CA Jr (2017) New 635
609 targets for rapid antidepressant action. *Prog Neurobiol* **152**, 636
610 21-37.
- 611 [28] Schrag A, Barone P, Brown RG, Leentjens AF, McDonald 637
612 WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sam- 638
613 paio C, Stebbins GT, Goetz CG (2007) Depression rating 639
614 scales in Parkinson's disease: Critique and recommenda- 640
615 tions. *Mov Disord* **22**, 1077-1092.
- [29] Richard IH, McDermott MP, Kurlan R, Lyness JM, Como 616
PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, 617
Brodsky M, Manning C, Marsh L, Shulman L, Fernandez 618
HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer 619
C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, 620
Press D, Hyson HC, McDonald W, Group S-PS (2012) 621
A randomized, double-blind, placebo-controlled trial of 622
antidepressants in Parkinson disease. *Neurology* **78**, 1229- 623
1236. 624
- [30] Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske 625
S, Bienfait K, Dicke A (2009) A controlled trial of antide- 626
pressants in patients with Parkinson disease and depression. 627
Neurology **72**, 886-892. 628
- [31] Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris 629
K, Corbett A, Dhall R, Ballard C (2014) Pimavanserin for 630
patients with Parkinson's disease psychosis: A randomised, 631
placebo-controlled phase 3 trial. *Lancet* **383**, 533-540. 632
- [32] Meltzer HY, Mills R, Revell S, Williams H, Johnson A, 633
Bahr D, Friedman JH (2010) Pimavanserin, a serotonin(2A) 634
receptor inverse agonist, for the treatment of parkinson's 635
disease psychosis. *Neuropsychopharmacology* **35**, 881-892. 636